JANX
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Janux Therapeutics, Inc. (JANX) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (A+); its weakest is Growth (D-). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | B (3.2) | D- (0.8) | C- (1.9) | C+ (2.7) | A+ (5.0) | C+ (2.7) |
| 2026-11-05 | C+ (2.7) | F (0.3) | C- (1.9) | B (3.2) | A+ (5.0) | C+ (2.6) |
| 2026-10-29 | C+ (2.7) | F (0.4) | C- (1.9) | B- (3.1) | A+ (5.0) | C+ (2.6) |
| 2026-10-22 | C+ (2.8) | F (0.4) | C- (1.9) | B- (2.9) | A+ (5.0) | C+ (2.6) |
| 2026-10-15 | C+ (2.8) | F (0.3) | C- (1.9) | B- (2.9) | A+ (5.0) | C+ (2.6) |